SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma.

导出 OA

翻译打印收藏纠错

作者： Alexander C,Leeksma ^[1] ; Ingrid A M,Derks ^[2] ; Brett,Garrick ^[3] ; Aldo,Jongejan ^[2] ; Martino,Colombo ^[3] ; Timon,Bloedjes ^[4] ; Torsten,Trowe ^[5] ; Jim C,Leisten ^[6] ; Michelle,Howarth ^[7] ; Mehnaz,Malek ^[4] ; Deborah S,Mortensen ^[8] ; Kate,Blease ^[4] ; Mathew C,Groza ^[4] ; Rama Krishna,Narla ^[8] ; Remco,Loos ^[8] ; Marie-José,Kersten ^[8] ; Perry D,Moerland ^[8] ; Jeroen E J,Guikema ^[6] ; Arnon P,Kater ^[1] ; Eric,Eldering ^[5] ; Ellen H,Filvaroff ^[7]

作者单位： Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands. ^[1] Department of Experimental Immunology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands. ^[2] Lymphoma and myeloma center Amsterdam (LYMMCARE), Cancer Center Amsterdam (CCA) and Amsterdam Infection and Immunity Institute (AIII), The Netherlands. ^[3] Translational Research, Bristol Myers Squibb, San Francisco, CA, USA. ^[4] Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands. ^[5] Bristol Myers Squibb's Center for Innovation and Translational Research Europe (CITRE), Seville, Spain. ^[6] Department of Pathology, Amsterdam University Medical Centers, Lymphoma and Myeloma Center Amsterdam (LYMMCARE), University of Amsterdam, The Netherlands. ^[7] Discovery, Bristol Myers Squibb, San Diego, CA, USA. ^[8]

关键词 MM NMD SMG1 UPR cancer therapy